[HTML][HTML] A review of hematological complications and treatment in COVID-19
AN Yazdani, A Abdi, P Velpuri, P Patel, N DeMarco… - Hematology …, 2023 - mdpi.com
COVID-19, caused by SARS-CoV-2, and its variants have spread rapidly across the globe in
the past few years, resulting in millions of deaths worldwide. Hematological diseases and …
the past few years, resulting in millions of deaths worldwide. Hematological diseases and …
[HTML][HTML] The Ways of the Virus: Interactions of Platelets and Red Blood Cells with SARS-CoV-2, and Their Potential Pathophysiological Significance in COVID-19
MA Panteleev, AN Sveshnikova… - International Journal of …, 2023 - mdpi.com
The hematological effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) are important in COVID-19 pathophysiology. However, the interactions of SARS-CoV-2 …
2) are important in COVID-19 pathophysiology. However, the interactions of SARS-CoV-2 …
[HTML][HTML] Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study
Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …
[HTML][HTML] Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial
Background The advantages and disadvantages of casirivimab-imdevimab for coronavirus
disease 2019 are not well understood. We conducted a systematic review and meta …
disease 2019 are not well understood. We conducted a systematic review and meta …
[HTML][HTML] Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
Y Liu, S Fan, A Xu, L Ge, X Wang, X Dong… - Frontiers in …, 2023 - frontiersin.org
Introduction: Randomized, controlled trials of molnupiravir in real-world use during the
Omicron wave are scarce. The frequency of hospitalization and death is low, so further …
Omicron wave are scarce. The frequency of hospitalization and death is low, so further …
[HTML][HTML] Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
Background Molnupiravir is being widely used as a treatment for coronavirus disease 2019
(COVID-19); however, its acceptability and safety in older patients aged≥ 80 years in real …
(COVID-19); however, its acceptability and safety in older patients aged≥ 80 years in real …
Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan
S Inaba, N Nishioka, H Okumura, K Nakao, Y Hattori… - 2023 - researchsquare.com
Molnupiravir is among the antiviral agents used to treat COVID-19; however, reported data
on the efficacy of this drug are based on results from unvaccinated patients. As such, the …
on the efficacy of this drug are based on results from unvaccinated patients. As such, the …
Divergences in Antiviral Therapy for Diabetic Patients with COVID-19
A Fitero, N Negrut, CD Nistor-Cseppento, DM Tit… - 2024 - preprints.org
Background: Patients with diabetes are particularly susceptible to COVID-19 infection, which
can result in severe respiratory illness. Methods: This study conducted a comparative as …
can result in severe respiratory illness. Methods: This study conducted a comparative as …
Liver injury in non-severe COVID-19 with various pandemic phases: a real-world study
J Winyupakorn, C Sangketchon, WDN Ayutthaya… - 2023 - researchsquare.com
The using of a variety of anti-COVID-19 medicines connected to the degree of liver
impairment in the short term was intriguing. To evaluate the dynamic course of liver injury in …
impairment in the short term was intriguing. To evaluate the dynamic course of liver injury in …